Jane Street
KNSA icon

Jane Street’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Jane Street’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2M Buy
41,500
+22,600
+120% +$1M ﹤0.01% 5095
2025
Q4 		$780K Buy
18,900
+11,800
+166% +$473K ﹤0.01% 6686
2025
Q3 		$276K Sell
7,100
-4,200
-37% -$136K ﹤0.01% 9071
2025
Q2 		$313K Buy
+11,300
New +$288K ﹤0.01% 7791
2024
Q2 		– Sell
-35,700
Closed -$704K – 9816
2024
Q1 		$704K Buy
+35,700
New +$697K ﹤0.01% 6082
2022
Q3 		– Sell
-56,000
Closed -$542K – 10088
2022
Q2 		$542K Buy
56,000
+31,000
+124% +$289K ﹤0.01% 6597
2022
Q1 		$249K Sell
25,000
-20,400
-45% -$216K ﹤0.01% 8689
2021
Q4 		$534K Buy
45,400
+28,500
+169% +$350K ﹤0.01% 7137
2021
Q3 		$192K Buy
+16,900
New +$220K ﹤0.01% 8876

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Jane Street's KNSA Position: Q1 2026 in Review

Jane Street sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 242,430 shares — an estimated $10.7M sold.

Jane Street first reported a position in KNSA in Q3 2020 and held it in 16 quarters. The position peaked at $17.9M in Q3 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Jane Street reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 242,430 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $10.7M.
  • Jane Street first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 16 quarters.
  • Jane Street's Kiniksa Pharmaceuticals position peaked at $17.9M in Q3 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.